Call for Papers  

Article Details


Recent Research in Selective Cyclin-Dependent Kinase 4 Inhibitors for Anti-Cancer Treatment

[ Vol. 16 , Issue. 36 ]

Author(s):

Ning Liu, Hao Fang, Yanling Li and Wenfang Xu   Pages 4869 - 4888 ( 20 )

Abstract:


It is well known that cyclins and cyclin-dependent kinases (CDKs) play essential roles in regulation of the cell cycle. In past two decades, the scientific researches suggest that the cyclin D1/ CDK4 complex is a key regulator of the transition through the G1 phase of the cell cycle. Moreover, deregulation of the cyclin D /CDK4 pathway has been identified in multiple tumor types. Thus, CDK4 is a genetically validated therapeutic target; hence, there has been a surge of interests in finding selective CDK4 inhibitors as anti-cancer agents. This review will give the recent progress in the studies of structure, functions of CDK4 and highly selective and potent CDK4 inhibitors.

Keywords:

Cell cycle,G1-phase,cyclin-dependent kinases,CDK4,tumor,selective inhibitors,anti-cancer agents

Affiliation:

, , , Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong University, 44 West Culture Road, 250012 Ji'nan, Shandong, P.R. China.



Read Full-Text article